Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
BioCryst Pharmaceuticals |
---|---|
Information provided by: | BioCryst Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00035022 |
The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.
Condition | Intervention | Phase |
---|---|---|
Leukemia, Lymphocytic Lymphoma |
Drug: BCX-1777 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies |
Estimated Enrollment: | 71 |
Study Start Date: | August 2001 |
Estimated Study Completion Date: | March 2004 |
Despite the great strides that have been made in improving the outcome with frontline programs of intensive chemotherapy in patients with aggressive T-cell malignancies, the prognosis with relapsed or refractory T-cell leukemias or lymphomas is poor. BCX-1777 is a purine nucleoside phosphorylase (PNP) inhibitor and a potential T-cell target therapy. The purpose of the phase I portion of the study is to determine the maximum tolerated dose (MTD) of BCX-1777 and the dose to be studied in the phase II portion of the study. The purpose of the phase II portion of the study is to determine the safety and efficacy of BCX-1777 in patients with relapsed or refractory aggressive T-cell malignancies. Patients who respond to BCX-1777 or have stable disease may be eligible to receive an additional course of treatment.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion:
United States, Texas | |
M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Deborah A. Thomas, M.D. | M.D. Anderson Cancer Center |
Study ID Numbers: | BC-01-02 |
Study First Received: | May 2, 2002 |
Last Updated: | January 12, 2006 |
ClinicalTrials.gov Identifier: | NCT00035022 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Leukemia, Lymphoma, T-Cell |
Lymphatic Diseases Leukemia Leukemia, Lymphoid Immunoproliferative Disorders Lymphoma, T-Cell |
Leukemia, T-Cell Lymphoproliferative Disorders Aggression Lymphoma |
Lymphatic Diseases Leukemia Neoplasms Leukemia, Lymphoid Immunoproliferative Disorders |
Neoplasms by Histologic Type Immune System Diseases Lymphoproliferative Disorders Lymphoma |